Source:http://linkedlifedata.com/resource/pubmed/id/10567899
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions |
umls-concept:C0011065,
umls-concept:C0017337,
umls-concept:C0027627,
umls-concept:C0030705,
umls-concept:C0035647,
umls-concept:C0079419,
umls-concept:C0086661,
umls-concept:C0208973,
umls-concept:C0332120,
umls-concept:C0376515,
umls-concept:C0441994,
umls-concept:C0597712,
umls-concept:C0853879,
umls-concept:C1517892,
umls-concept:C1704666
|
pubmed:issue |
6
|
pubmed:dateCreated |
2000-1-6
|
pubmed:abstractText |
Apoptosis is an important physiological process controlled by multiple genes, including c-myc, p53 and bcl-2, and its inhibition may lead to the development of human cancers. In this study, we analyzed expression of the c-myc gene using Northern blot and of the p53 and bcl-2 proteins by immuno-histochemistry in 175 breast tumor specimens obtained from patients with operable breast cancer. We evaluated the relation between expression of these 3 genes and (i) the main usual prognostic factors (tumor size, histo-prognostic grade, hormone receptors and number of positive nodes); (ii) the risk of death and relapse, taking into account these 4 factors, after a mean period of follow-up of 9.5 years (SD 2 years). Over-expression of c-myc, p53 and bcl-2 was observed in 35%, 23% and 63% of tumors, respectively. Over-expression of c-myc was strongly linked to the number of positive nodes (p = 0.0005). p53 protein expression was associated with both high-grade (p = 0.0001) and hormone receptor-negative (p = 0.0001) tumors. In contrast, bcl-2 protein over-expression was associated with the main favorable prognostic factors and, more particularly, with hormone receptor-positive tumors (p = 0.0001). Multivariate analysis, using the Cox model, showed that only 2 factors were independently linked to the risk of death: number of positive nodes, which increased the risk (p = 0.0001), and bcl-2 protein over-expression, which decreased the risk (p = 0.008). When bcl-2 over-expression was studied in relation to nodal status, hormone receptor status and chemo- and hormone therapy, no significant difference was observed between different subgroups of patients. bcl-2 expression was also associated with a significantly lower risk of distant metastasis (p = 0.04). In conclusion, bcl-2 expression characterizes a particular phenotype of breast cancer with a favorable prognosis, and it may therefore be used as a marker of long-term survival. Int. J. Cancer (Pred. Oncol.) 84:562-567, 1999.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0020-7136
|
pubmed:author | |
pubmed:copyrightInfo |
Copyright 1999 Wiley-Liss, Inc.
|
pubmed:issnType |
Print
|
pubmed:day |
22
|
pubmed:volume |
84
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
562-7
|
pubmed:dateRevised |
2007-7-24
|
pubmed:meshHeading |
pubmed-meshheading:10567899-Aged,
pubmed-meshheading:10567899-Apoptosis,
pubmed-meshheading:10567899-Breast Neoplasms,
pubmed-meshheading:10567899-Female,
pubmed-meshheading:10567899-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:10567899-Genes, myc,
pubmed-meshheading:10567899-Genes, p53,
pubmed-meshheading:10567899-Humans,
pubmed-meshheading:10567899-Immunohistochemistry,
pubmed-meshheading:10567899-Middle Aged,
pubmed-meshheading:10567899-Multivariate Analysis,
pubmed-meshheading:10567899-Neoplasm Metastasis,
pubmed-meshheading:10567899-Proto-Oncogene Proteins c-bcl-2,
pubmed-meshheading:10567899-RNA,
pubmed-meshheading:10567899-Risk,
pubmed-meshheading:10567899-Survival Rate,
pubmed-meshheading:10567899-Tumor Suppressor Protein p53
|
pubmed:year |
1999
|
pubmed:articleTitle |
c-myc, p53 and bcl-2, apoptosis-related genes in infiltrating breast carcinomas: evidence of a link between bcl-2 protein over-expression and a lower risk of metastasis and death in operable patients.
|
pubmed:affiliation |
Institut National de la Santé et de la Recherche Médicale (INSERM-U521), Institut Gustave Roussy, Villejuif, France.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|